<< Exhibitor
<< Press release
In order to promote innovative exchanges and cross-regional cooperation in the global in vitro diagnostics field, the 1st Global IVD Innovation Summit is scheduled to be held in Xiamen on March 22, 2026, during CACLP 2026. Hereby notify the relevant matters as follows:
As artificial intelligence and digital twin technologies rapidly reshape the global healthcare landscape, their integration into clinical practice, laboratory medicine, and biomedical research is opening new frontiers for precision, efficiency, and system-level optimization.
Amid the deepening implementation of the Healthy China 2030 strategy and the rapid convergence of a new global biotechnology revolution, in vitro diagnostics (IVD) has become more critical than ever.
The 11th China Experimental Medicine Conference, themed “Innovation Shaping the Future,” will be held from 21-22 March, 2026, in Xiamen.
As a vital link between innovation and clinical application, IVD distribution enterprises play an indispensable role in ensuring the efficient flow of diagnostic products and services.
Driven by rapid advances in healthcare technology, the IVD industry is entering a new era of innovation and growth. Enlightening Lab Med —— The 9th IVD Youth Entrepreneur Forum will take place on 21 March 2026 at the Xiamen International Expo Center.
As the global in vitro diagnostics (IVD) industry advances toward greater technological sophistication, intelligent automation, and broader clinical applications, the focus of innovation is shifting upstream. Beyond the development of cutting-edge instruments and assays, increasing attention is being placed on the foundational elements that enable performance and reliability—namely critical raw materials, core components, and robust standards systems. Breakthroughs in advanced materials, precision-engineered components, and cross-disciplinary integration are becoming central drivers of sustainable industry growth.
With less than one month remaining before its official opening, the 23rd China International In Vitro Diagnostics by CACLP, together with a series of academic conferences, industry forums, and business meetings, has entered its final countdown stage.
As the global in vitro diagnostics (IVD) industry undergoes rapid technological evolution and market restructuring, overseas expansion has become a key growth pathway for Chinese IVD companies.
To unlock the new growth momentum for the IVD industry and extend its value boundaries, CACLP 2026 will, for the first time, introduce the At-Home Testing Pavilion, taking place from 21–23 March 2026 in Hall 5, Xiamen International Expo Center.
<< Industry news
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026.
Group sales were +6% at constant exchange rates (CER), -5% when reported in CHF and +9% in USD, in the first three months, driven by high demand for our innovative medicines and diagnostics.
Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, announced today that it was granted CE marking under the European Union In Vitro Diagnostic Regulation (EU IVDR) for both its ArteraAI Prostate Biopsy Assay and ArteraAI Breast Cancer Assay, marking a major step in the company’s global expansion.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enhance Merck’s digital backbone as an AI-enabled enterprise. This multi-year investment, valued at up to $1 billion, will deploy an agentic platform across Merck’s research & development (R&D), manufacturing, commercial, and corporate functions – and includes Google Cloud engineers working alongside Merck teams to deploy Google Cloud’s most sophisticated AI, including Gemini Enterprise.
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.
Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.
It can be seen from analysis on major blood grouping analyzer-related patent applications published in the 3 years from 2018 to 2021 that benefited from the basically stable original technologies of the industry; domestic enterprises have continuously increased R&D inputs, constantly improved technical innovation capability, made breakthroughs in many technologies, and developed a batch of core components of instruments with independent intellectual property rights through follow-on R&D strategy.
Boehringer Ingelheim has launched a new artificial intelligence (AI) and machine learning (ML) centre in London, representing the company’s latest move to drive improved patient outcomes through the technologies’ application.
QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and CLIA waiver in February 2026.
QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenue for the first quarter of 2026, ended March 29, 2026, and provided an update on its full-year 2026 financial guidance. The Company also announced its plan to release its full first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes.
<< Video showcase
Talk with Jag Grewal at CACLP 2026
CACLP 2026 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 13th China IVD Industry Development Conference & The 11th China Experimental Medicine Conference
CACLP International Night 2026
The 1st Global IVD Innovation Summit
Go Global: China IVD International Forum 2026
CACLP 2025 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
The 12th China IVD Industry Development Conference (CIIDC)
The 10th China Experimental Medicine Conference (CEMC)
International Laboratory Medicine and In Vitro Diagnostic Forum
The 11th China IVD Industry Development Conference (CIIDC)
The 9th China Experimental Medicine Conference (CEMC)
CACLP 2024 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP APP is available for download now!
Gentian at CACLP 2023 Onsite
in.vent Diagnostics at CACLP 2023 Onsite
Charming Group at CACLP 2023 Onsite
Dialab at CACLP 2023 Onsite
JTC at CACLP 2023 Onsite
Certest at CACLP 2023 Onsite
<< Download centre
CACLP 2026 Floor Plan
CACLP 2026 Full Schedule
CACLP 2026 Exhibitor Manual
CACLP 2025 Post-show Report
CACLP 2025 Post-show Press Release
CACLP 2025 Exhibitor Manual
CACLP 2025 Floor Plan
CACLP 2025 Full Schedule
CACLP & CISCE 2024 Draw Global Attention to Innovations and Collaborations in IVD Industry
CACLP & CISCE to present the latest in IVD with 1300+ Exhibitors and 100+ Concurrent Activities this March in Chongqing.pdf
Copyright © 2026 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
